MEDP * Stock Overview Provides clinical research-based drug and medical device development services in North America, Europe, and Asia. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Medpace Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Medpace Holdings Historical stock prices Current Share Price US$7,176.00 52 Week High US$7,655.00 52 Week Low US$6,565.00 Beta 1.36 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change 58.41% 5 Year Change 359.26% Change since IPO 613.67%
Recent News & Updates
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Oct 22
Medpace Holdings, Inc. to Report Q3, 2024 Results on Oct 21, 2024 Sep 26
Second quarter 2024 earnings released: EPS: US$2.85 (vs US$2.00 in 2Q 2023) Jul 23
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Jul 23
Medpace Holdings, Inc. to Report Q2, 2024 Results on Jul 22, 2024 Jun 27
First quarter 2024 earnings released: EPS: US$3.33 (vs US$2.35 in 1Q 2023) Apr 23 See more updates
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Oct 22
Medpace Holdings, Inc. to Report Q3, 2024 Results on Oct 21, 2024 Sep 26
Second quarter 2024 earnings released: EPS: US$2.85 (vs US$2.00 in 2Q 2023) Jul 23
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Jul 23
Medpace Holdings, Inc. to Report Q2, 2024 Results on Jul 22, 2024 Jun 27
First quarter 2024 earnings released: EPS: US$3.33 (vs US$2.35 in 1Q 2023) Apr 23
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Apr 23
Insufficient new directors Apr 15
Medpace Holdings, Inc., Annual General Meeting, May 17, 2024 Apr 04
Medpace Holdings, Inc. to Report Q1, 2024 Results on Apr 22, 2024 Mar 29
Insufficient new directors Dec 05
Medpace Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2023 and 2024 Oct 25
Medpace Holdings, Inc. to Report Q3, 2023 Results on Oct 23, 2023 Sep 27
Insufficient new directors Sep 22
Second quarter 2023 earnings released: EPS: US$2.00 (vs US$1.52 in 2Q 2022) Jul 26
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2023 Jul 25
Insufficient new directors Jul 14
Medpace Holdings, Inc. to Report Q2, 2023 Results on Jul 24, 2023 Jul 06 Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Growth-Defensive Index
Insufficient new directors May 12
First quarter 2023 earnings released: EPS: US$2.35 (vs US$1.76 in 1Q 2022) Apr 28
Insufficient new directors Apr 26
Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2023 Feb 14
Insufficient new directors Jan 27
Medpace Holdings, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023 Jan 05
Medpace Holdings, Inc. Announces Resignation of Thomas C. King to Board Jan 04
Insufficient new directors Dec 15
Insufficient new directors Dec 01
CFO & Treasurer recently sold Mex$8.8m worth of stock Nov 18
Insufficient new directors Nov 17
Investor sentiment improved over the past week Nov 01
Third quarter 2022 earnings released: EPS: US$2.13 (vs US$1.35 in 3Q 2021) Oct 26
Medpace Holdings, Inc. (NasdaqGS:MEDP) announces an Equity Buyback for $500 million worth of its shares. Oct 26
Insufficient new directors Oct 25
Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2022 and 2023 Oct 25
Medpace Holdings, Inc. to Report Q3, 2022 Results on Oct 24, 2022 Sep 28
Chairman & CEO recently bought Mex$292m worth of stock Sep 23
Insufficient new directors Sep 22
Chairman & CEO recently bought Mex$207m worth of stock Sep 14
Investor sentiment deteriorated over the past week Sep 02
Insufficient new directors Aug 18
Second quarter 2022 earnings released: EPS: US$1.52 (vs US$1.11 in 2Q 2021) Jul 26
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022 Jul 26
Insufficient new directors Jul 25
Medpace Holdings, Inc. to Report Q2, 2022 Results on Jul 25, 2022 Jul 08
Insufficient new directors Jun 28
Insufficient new directors Jun 02
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022 Apr 26
Medpace Holdings, Inc., Annual General Meeting, May 20, 2022 Apr 07
Investor sentiment deteriorated over the past week Feb 25
Lead Independent Director recently bought Mex$1.5m worth of stock Feb 24
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 16
Medpace Holdings, Inc. Provides Consolidated Earnings Guidance for the Year 2022 Feb 15
Investor sentiment improved over the past week Nov 05
Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.16 in 3Q 2020) Oct 26
Second quarter 2021 earnings released: EPS US$1.11 (vs US$0.68 in 2Q 2020) Jul 28
Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2021 Apr 27
Executive Vice President of Operations recently sold Mex$22m worth of stock Mar 12
Medpace Holdings, Inc. to Report Q1, 2021 Results on Apr 26, 2021 Mar 11
Executive Vice President of Operations recently sold Mex$22m worth of stock Mar 06
Full year 2020 earnings released: EPS US$4.07 (vs US$2.79 in FY 2019) Feb 19
Revenue beats expectations Feb 19
Investor sentiment improved over the past week Feb 13
Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index Jan 28
Medpace Holdings, Inc. to Report Q4, 2020 Results on Feb 15, 2021 Jan 06 Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from S&P 600 Health Care (Sector)
Medpace Holdings, Inc. to Report Q3, 2020 Results on Oct 26, 2020 Sep 04
Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index Jul 05 Shareholder Returns MEDP * MX Life Sciences MX Market 7D 0% 0% 0% 1Y n/a 0% 0%
See full shareholder returns
Return vs Market: Insufficient data to determine how MEDP * performed against the MX Market .
Price Volatility Is MEDP *'s price volatile compared to industry and market? MEDP * volatility MEDP * Average Weekly Movement n/a Life Sciences Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stable Share Price: MEDP *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine MEDP *'s volatility change over the past year.
About the Company Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Show more Medpace Holdings, Inc. Fundamentals Summary How do Medpace Holdings's earnings and revenue compare to its market cap? MEDP * fundamental statistics Market cap Mex$215.07b Earnings (TTM ) Mex$7.39b Revenue (TTM ) Mex$41.88b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MEDP * income statement (TTM ) Revenue US$2.07b Cost of Revenue US$678.86m Gross Profit US$1.39b Other Expenses US$1.03b Earnings US$365.57m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 11.79 Gross Margin 67.22% Net Profit Margin 17.65% Debt/Equity Ratio 0%
How did MEDP * perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 13:27 End of Day Share Price 2024/11/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Medpace Holdings, Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Eric Coldwell Baird Ishan Majumdar Baptista Research Erin Wilson Wright Credit Suisse
Show 17 more analysts 
